During the past decade, Sarah Cannon Research Institute UK conducted 55 clinical trials. In the 10-year time frame, 55 clinical trials started and 18 clinical trials were completed, i.e. on average, 32.7% percent of trials that started reached the finish line to date. In the past 5 years, 26 clinical trials started and 12 clinical trials were completed. i.e. 46.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sarah Cannon Research Institute UK" #1 sponsor was "Pfizer" with 8 trials, followed by "Seagen Inc." with 8 trials sponsored, "BeiGene" with 6 trials sponsored, "Celgene" with 6 trials sponsored and "Daiichi Sankyo, Inc." with 6 trials sponsored. Other sponsors include 29 different institutions and companies that sponsored additional 27 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sarah Cannon Research Institute UK" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 5 trials as a collaborator, "AstraZeneca" with 3 trials as a collaborator, "Celgene Corporation" with 2 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 2 trials as a collaborator and "Medivation, Inc." with 2 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Sarah Cannon Research Institute UK" are "Breast Cancer" (6 trials), "Ovarian Cancer" (6 trials), "Carcinoma, Non-Small-Cell Lung" (5 trials), "Advanced Cancer" (3 trials) and "Advanced Solid Tumor" (3 trials). Many other conditions were trialed in "Sarah Cannon Research Institute UK" in a lesser frequency.

Most popular intervention types in "Sarah Cannon Research Institute UK" are "Drug" (62 trials), "Biological" (5 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Avelumab" (4 trials), "Gemcitabine" (4 trials), "Irinotecan" (4 trials) and "tucatinib" (4 trials). Other intervention names were less common.

The vast majority of trials in "Sarah Cannon Research Institute UK" are 61 trials for "All" genders, 4 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Sarah Cannon Research Institute UK". undefined are not yet recruiting, 16 are recruiting, 23 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 23 completed trials in Sarah Cannon Research Institute UK, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Sarah Cannon Research Institute UK, 29 "Phase 1" clinical trials were conducted, 34 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".